· Industry· 日本語で読む
Forbes Councils reports FDA De Novo authorization for Vitestro's Aletta blood-drawing robot
Forbes Councils reported that the FDA granted De Novo authorization to Vitestro's Aletta blood-drawing robot. According to an excerpt from the article, the authorization date was Aug. 19, and the device was the first standalone robotic system authorized to draw blood without hands-on operator involvement during needle insertion. However, the excerpt provided does not specify the authorization conditions or the operator's role in steps other than needle insertion.
What happened
A Forbes Councils article dated Nov. 17, 2026, reported that the FDA granted De Novo authorization on Aug. 19 to Aletta, a device made by the Dutch company Vitestro. According to the article excerpt, Aletta was the first standalone robotic system authorized to draw blood from a patient's arm without hands-on operator involvement during needle insertion.
Why it matters
The Forbes Councils report indicates that the FDA authorized Aletta as a blood-drawing robotic system that does not require hands-on operator involvement during needle insertion. For health care facilities, the report provides a basis for assessing how the device differs from conventional blood-drawing procedures, after reviewing the authorization conditions and the steps performed by people.
Analysis
The focus of the report is not the general idea of robots assisting with blood draws, but the claim that the FDA granted De Novo authorization to Aletta. The excerpt refers to the system locating a vein and inserting a needle, and identifies the absence of hands-on operator involvement during needle insertion as a feature of the authorization. However, it does not establish that the system performs every step involved in drawing blood without human involvement or that it can be used with all patients and in all settings. The applicable authorization conditions should be considered separately from the tasks people perform before and after needle insertion.
In a related article, we covered Vitestro's announcement that it raised $70 million in a Series B round to develop and commercialize Aletta in Vitestro raises $70 million in Series B funding to develop autonomous blood-drawing robot (March 13, 2026). The latest report points to a separate milestone — FDA authorization — in the context of that development and commercialization effort. However, the information provided does not establish a causal link between the funding and the authorization, or indicate the device's sales or deployment status after authorization.
For comparison with other uses of robots, we previously covered a report that Airbus had begun testing industrial humanoid robots for aircraft manufacturing in Airbus begins testing industrial humanoid robots (Jan. 22, 2026). That involves testing in a manufacturing setting, a different evaluation context from authorization of a medical device that inserts a needle into a patient's body. For Aletta, it is important to assess not only the robot's performance, but also clinical safety and the scope of human supervision in light of the authorization conditions. The two cases should not be treated as a single trend in “autonomous robots”; the tasks involved and the regulatory questions should be considered separately.
The points to watch are, first, the scope and conditions of the De Novo authorization; second, the operator's involvement in steps other than needle insertion; and third, clinical outcomes and actual use after authorization. These details are not available from the article excerpt provided.
Sources
Translated from the Japanese original: /news/forbes-councils-vitestro-no-saiketsu-robotto-to-fda-handan-w-cb4c12. The Japanese version is authoritative if they differ.